Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.13 (
protein kinase C
)
49,245
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Kyowa Hakko Kogyo is developing UCN-01, a selective but non-specific inhibitor of kinases with good activity against
protein kinase C
(
PKC
) and the cyclin-dependent kinases (CDKs). This hydroxylated derivative of staurosporine has potential for the treatmentfor cancer [154087], [311028], and may be useful in the treatment of chronic lymphocytic leukemia [312089]. It is in phase I clinical trials [321641], [326004], [326256]. At the 11th NCI-EORTC-AACR Symposium (Amsterdam, November 2000), a presentation was made on UCN-01. In the initial clinical trial, in which UCN-01 was administered by continuous infusion for 72 h, a prolonged half-life of 600 h was observed. The
MTD
was 42.5 mg/m2/day x 3. One patient with refractory melanoma achieved a partial response, another patient with refractory anaplastic large cell lymphoma had no evaluable diseasefor more than three years [391376].
...
PMID:UCN-01 Kyowa Hakko Kogyo Co. 1181 46
